ELVN
Enliven Therapeutics, Inc. NASDAQ Listed Mar 12, 2020$48.87
Mkt Cap $3.5B
52w Low $14.79
71.7% of range
52w High $62.32
50d MA $56.22
200d MA $39.22
P/E (TTM)
-29.8x
EV/EBITDA
—
P/B
6.0x
Debt/Equity
0.0x
ROE
-22.6%
P/FCF
-39.3x
RSI (14)
20.30
ATR (14)
$2.20
Beta
0.49
50d MA
$56.22
200d MA
$39.22
Avg Volume
1.2M
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
6200 Lookout Road · Boulder, CO 80301 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | AMC | -0.39 | -0.49 | -26.6% | 59.70 | -0.6% | +1.0% | +0.3% | -1.7% | -1.1% | -1.5% | — |
| May 7, 2026 | AMC | -0.44 | -0.38 | +13.6% | 40.29 | +3.2% | +1.1% | -2.8% | +6.8% | +3.0% | -1.1% | — |
| Mar 3, 2026 | AMC | -0.42 | -0.48 | -14.3% | 28.75 | -0.6% | +4.3% | -2.3% | +0.5% | +1.0% | +1.7% | — |
| Nov 12, 2025 | AMC | -0.43 | -0.32 | +25.6% | 20.30 | +0.0% | -0.1% | +8.9% | -1.4% | +3.8% | -2.2% | — |
| Aug 13, 2025 | AMC | -0.53 | -0.49 | +7.5% | 19.99 | -0.3% | -1.1% | +2.3% | -2.3% | +0.1% | -0.5% | — |
| May 14, 2025 | AMC | -0.51 | -0.57 | -11.8% | 19.89 | -2.3% | -10.4% | -5.4% | -0.1% | +3.1% | -2.6% | — |
| Mar 13, 2025 | AMC | -0.53 | -0.46 | +13.2% | 20.29 | +4.0% | +2.2% | +1.4% | -3.6% | +3.0% | +0.1% | — |
| Nov 13, 2024 | AMC | -0.52 | -0.48 | +7.7% | 25.80 | +2.2% | -3.4% | -2.0% | +2.0% | +5.1% | -2.9% | — |
| Aug 13, 2024 | AMC | -0.58 | -0.41 | +29.3% | 21.52 | +4.3% | +1.3% | +9.0% | -0.3% | -0.8% | -5.2% | — |
| May 14, 2024 | AMC | -0.58 | -0.54 | +6.9% | 23.87 | +4.1% | +0.5% | -0.8% | -3.2% | +4.2% | -4.6% | — |
| Mar 14, 2024 | AMC | -0.56 | -0.47 | +16.1% | 11.54 | -3.6% | +3.7% | +5.6% | +38.8% | +9.5% | -6.0% | — |
| Nov 9, 2023 | AMC | -0.49 | -0.51 | -4.1% | 11.55 | +0.1% | -1.5% | -4.2% | +0.9% | -0.5% | -4.8% | — |
| Aug 10, 2023 | AMC | -0.40 | -0.41 | -2.5% | 17.52 | -1.4% | +0.1% | -6.2% | +0.1% | -6.9% | +6.0% | — |
| May 11, 2023 | AMC | -0.67 | -0.80 | -19.4% | 19.10 | -0.5% | +1.6% | +2.2% | -0.1% | +0.9% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18 | Barclays | Initiates | Overweight | $78 | $59.54 | $59.79 | +0.4% | +0.9% | -1.1% | -0.8% | +1.5% | +2.2% |
| Aug 18 | William Blair | Initiates | Outperform | — | $59.54 | $59.79 | +0.4% | +0.9% | -1.1% | -0.8% | +1.5% | +2.2% |
| Jun 9 | Stifel | Initiates | Buy | $60 | $33.63 | $34.62 | +2.9% | +7.4% | +2.5% | +9.1% | +14.3% | -8.2% |
| May 12 | Guggenheim | Initiates | Buy | $80 | $39.59 | $40.65 | +2.7% | +6.8% | +3.0% | -1.1% | -4.0% | -4.1% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.53 | $35.66 | +0.4% | +10.6% | -1.2% | -5.8% | +7.1% | -3.6% |
| Mar 25 | Mizuho | Maintains | Outperform → Outperform | — | $31.15 | $33.76 | +8.4% | +14.1% | +10.6% | -1.2% | -5.8% | +7.1% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.65 | $20.04 | +2.0% | +5.0% | +0.4% | -5.5% | +1.7% | +8.3% |
| Jun 16 | Baird | Maintains | Outperform → Outperform | — | $21.91 | $23.38 | +6.7% | +5.4% | -5.6% | -1.1% | -1.3% | -4.7% |
| May 16 | Jones Trading | Maintains | Buy → Buy | — | $17.82 | $17.73 | -0.5% | -5.4% | -0.1% | +3.1% | -2.6% | -0.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.89 | $19.44 | -2.3% | -10.4% | -5.4% | -0.1% | +3.1% | -2.6% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.92 | $20.64 | -1.3% | +0.8% | +6.5% | -5.1% | -3.5% | +4.5% |
| Nov 15 | Baird | Maintains | Outperform → Outperform | — | $24.92 | $25.00 | +0.3% | -2.0% | +2.0% | +5.1% | -2.9% | -0.1% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.54 | $25.70 | +0.6% | +1.8% | -2.7% | +0.8% | +7.9% | -0.3% |
| Mar 29 | Jefferies | Maintains | Buy → Buy | — | $23.49 | $23.75 | +1.1% | +2.0% | -7.6% | -1.1% | +1.1% | +2.7% |
| Mar 3 | TD Cowen | Maintains | Outperform → Outperform | — | $23.45 | $24.80 | +5.8% | -5.8% | -1.0% | -3.2% | +5.9% | -5.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,100 | $59.35 | $65K | 25,000 | -0.79% | -0.24% |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3,900 | $58.37 | $228K | 26,100 | -0.79% | -0.24% |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,388 | $59.35 | $82K | 40,036 | -0.79% | -0.24% |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 4,630 | $58.35 | $270K | 41,424 | -0.79% | -0.24% |
| Aug 4, 2026 | Derynck Mika K | — | Sell | 158,795 | $60.21 | $9.6M | — | +0.32% | +0.24% |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 63 | $53.92 | $3K | 25,000 | -2.72% | +1.93% |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,184 | $53.42 | $117K | 25,063 | -2.72% | +1.93% |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,063 | $52.39 | $108K | 27,247 | -2.72% | +1.93% |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 459 | $51.55 | $24K | 29,310 | -2.72% | +1.93% |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 231 | $50.05 | $12K | 29,769 | -2.72% | +1.93% |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 123 | $53.87 | $7K | 46,054 | -2.72% | +1.93% |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,638 | $53.38 | $141K | 46,177 | -2.72% | +1.93% |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,564 | $52.32 | $134K | 48,815 | -2.72% | +1.93% |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 369 | $51.48 | $19K | 51,379 | -2.72% | +1.93% |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 324 | $49.97 | $16K | 51,748 | -2.72% | +1.93% |
| Jul 6, 2026 | Kunkel Lori Anne | — | Sell | 5,889 | $50.84 | $299K | 41,884 | +2.72% | +2.76% |
| Jul 6, 2026 | Kunkel Lori Anne | — | Sell | 4,111 | $49.98 | $205K | 47,773 | +2.72% | +2.76% |
| Jun 22, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 46,776 | $45.00 | $2.1M | 6,555,102 | +2.83% | -3.92% |
| Jun 22, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 787,024 | $45.38 | $35.7M | 6,601,878 | +2.83% | -3.92% |
| Jun 22, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 1,477 | $45.00 | $66K | 219,405 | +2.83% | -3.92% |
| Jun 22, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 24,846 | $45.38 | $1.1M | 220,882 | +2.83% | -3.92% |
| Jun 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,133 | $44.74 | $51K | 25,000 | +5.74% | +1.54% |
| Jun 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,599 | $43.87 | $114K | 26,133 | +5.74% | +1.54% |
| Jun 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,268 | $42.83 | $54K | 28,732 | +5.74% | +1.54% |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,238 | $44.75 | $55K | 51,000 | +5.74% | +1.54% |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,401 | $43.86 | $149K | 52,238 | +5.74% | +1.54% |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,379 | $42.78 | $59K | 55,639 | +5.74% | +1.54% |
| Jun 15, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 272,322 | $45.02 | $12.3M | 7,388,902 | +0.54% | +2.83% |
| Jun 15, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 9,086 | $45.02 | $409K | 245,728 | +0.54% | +2.83% |
| Jun 5, 2026 | Kunkel Lori Anne | — | Sell | 354 | $35.82 | $13K | 51,884 | +2.46% | +0.45% |
8-K · 7.01
! Medium
Enliven Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 11
8-K · 5.03
! Medium
Enliven Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 10
8-K
Enliven Therapeutics, Inc. -- 8-K Filing
Enliven Therapeutics (ELVN) is advancing ELVN-001 toward Phase 3 trials with a pivotal data readout and regulatory interactions planned for 2026, signaling potential milestone catalysts ahead.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 6,829,246 | $268M | Reduced | Mar 2026 |
| 2 | Blackrock, Inc. | 4,359,704 | $221M | New | Jun 2026 |
| 3 | Citadel Advisors Llc | 4,137,984 | $210M | Added | Jun 2026 |
| 4 | Vanguard Capital Management Llc | 2,569,002 | $130M | New | Jun 2026 |
| 5 | Bellevue Group Ag | 2,320,867 | $91M | New | Mar 2026 |
| 6 | Siren, L.l.c. | 1,774,411 | $90M | New | Jun 2026 |
| 7 | Fairmount Funds Management Llc | 1,855,644 | $73M | Reduced | Mar 2026 |
| 8 | Pictet Asset Management Holding Sa | 1,161,784 | $59M | Reduced | Jun 2026 |
| 9 | Vr Adviser, Llc | 3,226,331 | $50M | — | Dec 2025 |
| 10 | Vanguard Portfolio Management Llc | 562,763 | $29M | New | Jun 2026 |
| 11 | Millennium Management Llc | 411,362 | $21M | Added | Jun 2026 |
| 12 | Nuveen, Llc | 374,217 | $19M | Added | Jun 2026 |
| 13 | Seven Fleet Capital Management Lp | 365,386 | $19M | New | Jun 2026 |
| 14 | Spruce Street Capital Lp | 329,006 | $17M | New | Jun 2026 |
| 15 | Jennison Associates Llc | 309,219 | $16M | New | Jun 2026 |
| 16 | Avidity Partners Management Lp | 400,000 | $16M | New | Mar 2026 |
| 17 | Assenagon Asset Management S.a. | 306,574 | $16M | New | Jun 2026 |
| 18 | D. E. Shaw & Co., Inc. | 305,703 | $16M | Added | Jun 2026 |
| 19 | Northern Trust Corp | 372,316 | $15M | Added | Mar 2026 |
| 20 | Stempoint Capital Lp | 363,438 | $14M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.49B
Enterprise Value
$2.31B
P/E (TTM)
-29.80x
Forward P/E
—
PEG Ratio
2.65x
P/B
6.03x
P/S
—
P/FCF
-39.30x
EV/EBITDA
—
Shares Out
56.7M
Financials (TTM)
Revenue
$0
Net Income
-$105.9M
EBITDA
-$105.8M
Free Cash Flow
-$70.5M
Op Cash Flow
-$70.3M
EPS Basic
$-1.83
EPS Diluted
$-1.64
EPS Forward
$-2.02
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$476.2M
Total Liab.
$16.7M
Total Equity
$459.6M
Cash
$462.6M
LT Debt
$0
Book Value/Sh
$8.11
Debt/Equity
0.00x
Current Ratio
28.66
Quick Ratio
28.66
Returns & Growth
ROE
-22.6%
ROA
-21.8%
ROIC
-26.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+3.2%
Price Returns
2W
-17.6%
1M
-18.3%
3M
+6.3%
6M
+68.3%
12M
+145.3%
Technicals
52W High
$62.32
52W Low
$14.79
50d MA
$56.22
200d MA
$39.22
RSI (14)
20.30
ATR (14)
$2.20
Beta
0.49
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$43.33
High
$52.00
Low
$39.00
Median
$39.00
Data updated apr 25, 2026 7:00am
· Source: financialmodelingprep.com